A plain-language guide

Atypical hemolytic uremic syndrome

What is known, what is still uncertain, and what is actively debated, written plainly, and built only from published medical research.

Early map · 8 sourced statements Every statement names its source Updated 2026-06-11
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Atypical hemolytic uremic syndrome is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What it is

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disorder in which an overactive complement system damages small blood vessels, causing the destruction of red blood cells, a low platelet count, and acute kidney injury.

Signs and symptoms

Acute kidney injury

Damage to the small vessels of the kidney can lead to acute kidney injury, a sudden drop in kidney function that is common in aHUS.

Limited evidenceSource: ORPHA:2134
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:36323601
Notesplain_language confirmed from PMID:36323601 via curation 2026-06-11.
Last reviewed2026-06-11

Thrombocytopenia

aHUS lowers the platelet count (thrombocytopenia) because platelets are consumed in the damaged vessels.

Limited evidenceSource: ORPHA:2134
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:36323601
Notesplain_language confirmed from PMID:36323601 via curation 2026-06-11.
Last reviewed2026-06-11

Microangiopathic hemolytic anemia

In aHUS, red blood cells are torn apart as they pass through damaged small vessels, a process called microangiopathic hemolytic anemia.

Limited evidenceSource: ORPHA:2134
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:36323601
Notesplain_language confirmed from PMID:36323601 via curation 2026-06-11.
Last reviewed2026-06-11

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

Ravulizumab

Ravulizumab is a long-acting medicine that blocks the complement protein C5, given by infusion to control aHUS and protect the kidneys.

Used to help with: Atypical hemolytic uremic syndrome.

Limited evidenceSource: PMID:32299680
The source text this rests on
“Ravulizumab is a long-acting C5…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:32299680 via curation 2026-06-11
Last reviewed2026-06-11

Turn this into questions for your doctor

The hardest part is often knowing what to ask. PatientLead Health helps families turn what is on this page into the right questions for their care team.

Prepare for your appointment with PatientLead Health →

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.

Where this comes from

This guide is built from 2 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:2134 · Orphanet/HPO annotations for Atypical hemolytic uremic syndrome
PMID:32299680 · The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndro